Suppr超能文献

法匹拉韦和2'-C-甲基胞苷三磷酸对人及小鼠诺如病毒RNA聚合酶抑制特性的生化评估

Biochemical Evaluation of the Inhibition Properties of Favipiravir and 2'-C-Methyl-Cytidine Triphosphates against Human and Mouse Norovirus RNA Polymerases.

作者信息

Jin Zhinan, Tucker Kathryn, Lin Xiaoyan, Kao C Cheng, Shaw Ken, Tan Hua, Symons Julian, Behera Ishani, Rajwanshi Vivek K, Dyatkina Natalia, Wang Guangyi, Beigelman Leo, Deval Jerome

机构信息

Alios BioPharma Inc., South San Francisco, California, USA

Alios BioPharma Inc., South San Francisco, California, USA.

出版信息

Antimicrob Agents Chemother. 2015 Dec;59(12):7504-16. doi: 10.1128/AAC.01391-15. Epub 2015 Sep 21.

Abstract

Norovirus (NoV) is a positive-sense single-stranded RNA virus that causes acute gastroenteritis and is responsible for 200,000 deaths per year worldwide. No effective vaccine or treatment is available. Recent studies have shown that the nucleoside analogs favipiravir (T-705) and 2'-C-methyl-cytidine (2CM-C) inhibit NoV replication in vitro and in animal models, but their precise mechanism of action is unknown. We evaluated the molecular interactions between nucleoside triphosphates and NoV RNA-dependent RNA polymerase (NoVpol), the enzyme responsible for replication and transcription of NoV genomic RNA. We found that T-705 ribonucleoside triphosphate (RTP) and 2CM-C triphosphate (2CM-CTP) equally inhibited human and mouse NoVpol activities at concentrations resulting in 50% of maximum inhibition (IC50s) in the low micromolar range. 2CM-CTP inhibited the viral polymerases by competing directly with natural CTP during primer elongation, whereas T-705 RTP competed mostly with ATP and GTP at the initiation and elongation steps. Incorporation of 2CM-CTP into viral RNA blocked subsequent RNA synthesis, whereas T-705 RTP did not cause immediate chain termination of NoVpol. 2CM-CTP and T-705 RTP displayed low levels of enzyme selectivity, as they were both recognized as substrates by human mitochondrial RNA polymerase. The level of discrimination by the human enzyme was increased with a novel analog of T-705 RTP containing a 2'-C-methyl substitution. Collectively, our data suggest that 2CM-C inhibits replication of NoV by acting as a classic chain terminator, while T-705 may inhibit the virus by multiple mechanisms of action. Understanding the precise mechanism of action of anti-NoV compounds could provide a rational basis for optimizing their inhibition potencies and selectivities.

摘要

诺如病毒(NoV)是一种正链单链RNA病毒,可引起急性肠胃炎,在全球每年导致20万人死亡。目前尚无有效的疫苗或治疗方法。最近的研究表明,核苷类似物法匹拉韦(T-705)和2'-C-甲基胞苷(2CM-C)在体外和动物模型中可抑制NoV复制,但其确切作用机制尚不清楚。我们评估了三磷酸核苷与NoV RNA依赖性RNA聚合酶(NoVpol)之间的分子相互作用,NoVpol是负责NoV基因组RNA复制和转录的酶。我们发现,T-705核糖核苷三磷酸(RTP)和2CM-C三磷酸(2CM-CTP)在低微摩尔范围内导致最大抑制率50%(IC50)的浓度下,同等程度地抑制人和小鼠的NoVpol活性。2CM-CTP在引物延伸过程中通过直接与天然CTP竞争来抑制病毒聚合酶,而T-705 RTP在起始和延伸步骤主要与ATP和GTP竞争。将2CM-CTP掺入病毒RNA会阻断后续的RNA合成,而T-705 RTP不会导致NoVpol立即链终止。2CM-CTP和T-705 RTP表现出较低的酶选择性水平,因为它们都被人线粒体RNA聚合酶识别为底物。含有2'-C-甲基取代的T-705 RTP新型类似物增加了人酶的识别水平。总体而言,我们的数据表明,2CM-C通过作为经典的链终止剂来抑制NoV复制,而T-705可能通过多种作用机制来抑制病毒。了解抗NoV化合物的确切作用机制可为优化其抑制效力和选择性提供合理依据。

相似文献

2
Distinct Effects of T-705 (Favipiravir) and Ribavirin on Influenza Virus Replication and Viral RNA Synthesis.
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6679-6691. doi: 10.1128/AAC.01156-16. Print 2016 Nov.
3
Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase.
Antimicrob Agents Chemother. 2013 Nov;57(11):5202-8. doi: 10.1128/AAC.00649-13. Epub 2013 Aug 5.
4
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase.
Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449-463. doi: 10.2183/pjab.93.027.
5
The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon.
Antimicrob Agents Chemother. 2014 Aug;58(8):4675-81. doi: 10.1128/AAC.02546-13. Epub 2014 Jun 2.
6
Characterization of susceptibility variants of influenza virus grown in the presence of T-705.
J Pharmacol Sci. 2014;126(3):281-4. doi: 10.1254/jphs.14156sc. Epub 2014 Oct 9.
7
Favipiravir (T-705) inhibits in vitro norovirus replication.
Biochem Biophys Res Commun. 2012 Aug 10;424(4):777-80. doi: 10.1016/j.bbrc.2012.07.034. Epub 2012 Jul 15.
8
Inhibition of norovirus replication by the nucleoside analogue 2'-C-methylcytidine.
Biochem Biophys Res Commun. 2012 Nov 2;427(4):796-800. doi: 10.1016/j.bbrc.2012.10.003. Epub 2012 Oct 9.
9
Molecular Basis for the Selective Inhibition of Respiratory Syncytial Virus RNA Polymerase by 2'-Fluoro-4'-Chloromethyl-Cytidine Triphosphate.
PLoS Pathog. 2015 Jun 22;11(6):e1004995. doi: 10.1371/journal.ppat.1004995. eCollection 2015 Jun.
10
Biochemical Effect of Resistance Mutations against Synergistic Inhibitors of RSV RNA Polymerase.
PLoS One. 2016 May 10;11(5):e0154097. doi: 10.1371/journal.pone.0154097. eCollection 2016.

引用本文的文献

1
Mechanism and spectrum of inhibition of viral polymerases by 2'-deoxy-2'-β-fluoro-4'-azidocytidine or azvudine.
NAR Mol Med. 2025 Aug 11;2(3):ugaf029. doi: 10.1093/narmme/ugaf029. eCollection 2025 Jul.
2
Human norovirus cultivation systems and their use in antiviral research.
J Virol. 2024 Apr 16;98(4):e0166323. doi: 10.1128/jvi.01663-23. Epub 2024 Mar 12.
3
Favipiravir induces HuNoV viral mutagenesis and infectivity loss with clinical improvement in immunocompromised patients.
Clin Immunol. 2024 Feb;259:109901. doi: 10.1016/j.clim.2024.109901. Epub 2024 Jan 12.
4
Antiviral agents and disinfectants for foot‑and‑mouth disease (Review).
Biomed Rep. 2023 Jul 18;19(3):57. doi: 10.3892/br.2023.1639. eCollection 2023 Sep.
5
A comprehensive update on the structure and synthesis of potential drug targets for combating the coronavirus pandemic caused by SARS-CoV-2.
Arch Pharm (Weinheim). 2022 May;355(5):e2100382. doi: 10.1002/ardp.202100382. Epub 2022 Jan 17.
7
Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review.
Ther Adv Infect Dis. 2021 Dec 4;8:20499361211063016. doi: 10.1177/20499361211063016. eCollection 2021 Jan-Dec.
8
Current and Future Antiviral Strategies to Tackle Gastrointestinal Viral Infections.
Microorganisms. 2021 Jul 27;9(8):1599. doi: 10.3390/microorganisms9081599.
10
Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone.
Curr Pharmacol Rep. 2021;7(2):49-54. doi: 10.1007/s40495-021-00253-w. Epub 2021 Feb 18.

本文引用的文献

1
Subgenomic promoter recognition by the norovirus RNA-dependent RNA polymerases.
Nucleic Acids Res. 2015 Jan;43(1):446-60. doi: 10.1093/nar/gku1292. Epub 2014 Dec 17.
2
Enteric bacteria promote human and mouse norovirus infection of B cells.
Science. 2014 Nov 7;346(6210):755-9. doi: 10.1126/science.1257147.
3
Favipiravir elicits antiviral mutagenesis during virus replication in vivo.
Elife. 2014 Oct 21;3:e03679. doi: 10.7554/eLife.03679.
4
Prophylactic treatment with the nucleoside analogue 2'-C-methylcytidine completely prevents transmission of norovirus.
J Antimicrob Chemother. 2015 Jan;70(1):190-7. doi: 10.1093/jac/dku363. Epub 2014 Sep 16.
5
Nitazoxanide: a first-in-class broad-spectrum antiviral agent.
Antiviral Res. 2014 Oct;110:94-103. doi: 10.1016/j.antiviral.2014.07.014. Epub 2014 Aug 7.
6
Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral.
J Antimicrob Chemother. 2014 Oct;69(10):2770-84. doi: 10.1093/jac/dku209. Epub 2014 Jun 20.
7
Norovirus: targets and tools in antiviral drug discovery.
Biochem Pharmacol. 2014 Sep 1;91(1):1-11. doi: 10.1016/j.bcp.2014.05.021. Epub 2014 Jun 2.
9
Structural bases of norovirus RNA dependent RNA polymerase inhibition by novel suramin-related compounds.
PLoS One. 2014 Mar 12;9(3):e91765. doi: 10.1371/journal.pone.0091765. eCollection 2014.
10
Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model.
Antiviral Res. 2014 May;105:17-21. doi: 10.1016/j.antiviral.2014.02.014. Epub 2014 Feb 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验